Overview

Effect of Lifitegrast 5% on Tear Film Markers

Status:
Withdrawn

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the duration of time (in weeks) for improvement in objective dry eye markers for people who are placed on lifitegrast 0.5% (Xiidra®), an FDA-approved therapy for dry eyes.

Phase:

Phase 4

Details

Lead Sponsor:

Weill Medical College of Cornell University

Collaborators:

Novartis
Shire Human Genetic Therapies, Inc.

Treatments:

Lifitegrast
Ophthalmic Solutions
Pharmaceutical Solutions